Coronary disease & ACS

Edetate Disodium–Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial

JAMAPublished Randomised controlled trial

Primary resultResult — go to the resultAdjusted hazard ratio 0.93 95% CI 0.76–1.16

Authors' conclusion

Despite effectively reducing blood lead levels, EDTA chelation was not effective in reducing cardiovascular events in stable patients with coronary artery disease who have diabetes and a history of MI.

Study context

Population
Patients aged ≥50 years with DM and myocardial infarction (MI) ≥6 weeks before recruitmentreceived ≥1 infusion
Participants
959 patients
Comparison
EDTA-based chelation vs placebo infusions
  • Chelationn = 483
  • Placebon = 476reference
Primary endpoint
Composite of:
  • All-cause mortality
  • MI
  • Stroke
  • Coronary revascularization
  • Hospitalization for unstable angina
Follow-up
Median 48 months
Methodological details2 × 2 factorial, double-masked, placebo-controlled, multicenter (88 sites, US and Canada)
  • 2 × 2 factorial
  • Double-masked
  • Placebo-controlled
  • Multicenter (88 sites, US and Canada)

Primary result

As reported in the abstract

Adjusted hazard ratio

0.93

95% CI 0.76–1.16

P = 0.53

Events by treatment group

Chelationvs Placebo
adjusted HR 0.93 (95% CI 0.76–1.16); P = 0.53

Further findings

Primary end point, 5-year cumulative incidence

OutcomeChelationPlaceboAdjusted HR (95% CI)
CV death, MI or stroke18.4%19.7%0.89 (0.66–1.19)
All-cause death17.4%17.6%0.96 (0.71–1.30)
OutcomeChelationPlaceboμg/L
Blood lead level, baseline to infusion 40median 3.46 μg/L8.7
Baseline9.03 μg/L9.3
Blood lead level, baseline to infusion 40 — Chelation reduced median blood lead levels
P < .001

Original publication

Edetate Disodium–Based Chelation for Patients With a Previous Myocardial Infarction and Diabetes: TACT2 Randomized Clinical Trial. JAMA. Published 10 September 2024. doi:10.1001/jama.2024.11463

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.